Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging

Table 4 Clinical side effects induced by sorafenib in patients with advanced hepatocellular carcinoma and association with outcome

Ref.	Side effect	Patients (n)	Study design	Impact on survival	Impact on other parameters	Predictive value
Otsuka et al[42]	Skin reaction	94	Retrospective	Better OS	No impact on ORR, DCR, and TTP	No
Vincenzi et al[45]		65	Retrospective	Trend to a better OS	Better DCR	Early skin toxicity could predict efficacy of sorafenib
					Better TTP
Di Costanzo et al[43]		65	Retrospective	Better OS	Not reported	Skin toxicity could predict survival
Shomura et al[44]		37	Retrospective	Better OS	Better DCR	Skin toxicity could predict efficacy
Reig et al[46]		147	Prospective	Better OS	Better TTP	Early skin reaction could predict efficacy of sorafenib and survival
Otsuka et al[42]	Arterial hypertension	94	Retrospective	No impact	No impact	No
Estfan et al[55]		41	Retrospective	Better OS	Trend to better TTP

DCR: Disease control rate; OS: Overall survival; ORR: Objective response rate; TTP: Time to progression.